Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Non-Current Assets (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Non-Current Assets for 16 consecutive years, with $86.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 2.44% to $86.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $351.2 million, a 11.49% decrease, with the full-year FY2025 number at $86.9 million, down 2.44% from a year prior.
  • Non-Current Assets was $86.9 million for Q4 2025 at Anika Therapeutics, down from $87.8 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $188.8 million in Q1 2021 to a low of $86.9 million in Q4 2025.
  • A 5-year average of $142.3 million and a median of $174.0 million in 2023 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: grew 1.03% in 2023, then tumbled 44.39% in 2024.
  • Anika Therapeutics' Non-Current Assets stood at $179.0 million in 2021, then rose by 0.32% to $179.6 million in 2022, then tumbled by 40.24% to $107.3 million in 2023, then fell by 16.99% to $89.1 million in 2024, then decreased by 2.44% to $86.9 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Non-Current Assets are $86.9 million (Q4 2025), $87.8 million (Q3 2025), and $88.4 million (Q2 2025).